Thomson Reuters White Paper Explores the Role of Biomarkers in Clinical Trials and Drug Development

    PHILADELPHIA and LONDON, Jan. 12 /CNW/ -- Thomson Reuters today announced
that it has published a new white paper on the topic of biomarkers drawing on
expert insight from academics and key players in the pharmaceuticals industry.
 Called "Biomarkers: An Indispensable Addition to the Drug Development
Toolkit," it explores the role of biomarkers as evaluative tools in addressing
some of the challenges seen in clinical research and  their potential to
improve decision making, accelerate drug development and reduce development

    Used as a way to measure normal biological processes in the body,
pathological processes, or the response of the body to a therapeutic
intervention, Biomarkers have become an essential part of clinical development
because they potentially offer a faster route to market versus the
conventional drug development approach, where success rates have steadily
declined in recent years. Attrition rates for drugs in discovery and
development are currently very high with less than 10% of tested products
entering phase I trials. With increasing costs involved in the drug
development process, and growing concern that fewer drugs are making it
through to the marketplace each year, the pharmaceutical industry is embracing
biomarkers as a way of predicting a drug candidate's performance early and
with a greater degree of certainty.

    "The FDA, as well as academic and research organizations, have recognized
Biomarkers as having great potential to speed the development and approval of
medical products," said Wendy Hamilton, vice president of product strategy and
marketing, Scientific business of Thomson Reuters. "Because biomarkers can
predict drug efficacy and safety more quickly than conventional clinical
endpoints, they hold the potential to substantially accelerate product
development, and because they help to identify earlier those drug candidates
that are likely to fail, they reduce drug development costs. In addition,
biomarkers could revolutionize therapeutic treatments in areas such as
oncology, with their capacity to tailor therapies to specific individuals."

    "Biomarkers such as Her2 have already shown their effectiveness and
benefit in clinical trials," said Colin Williams, product manager, biology &
bioinformatics, Scientific business of Thomson Reuters. "Many other biomarkers
are following suit in clinical research but selecting the correct biomarker
can be a real challenge. Identifying the correct biomarker in clinical studies
can mean the difference between a drug candidate being approved or not, which
has profound implications for both the patients awaiting treatment and the
financial security of the drug company involved."

    Thomson Reuters has expanded the availability of BIOMARKERcenter, its
unique comprehensive resource for biomarker intelligence. BIOMARKERcenter is
now available through several delivery options: as a subscription option to
users of Prous Science Integrity(R), as an XML feed for in-house
bioinformatics solutions and also as a standalone web application. This
solution covers biomarkers identified in literature, patents, conferences,
clinical trial information, and other sources for all major therapeutic areas
and is the first to provide the pharmaceutical industry with a framework for
assessing the potential of a biomarker. BIOMARKERcenter is the most
comprehensive resource of its kind and continues to expand rapidly, with more
than 2,000 different biomarkers, and 13,000 unique uses of these biomarkers
within its database.

    For further information about BIOMARKERcenter, please go to:

    To read the full white paper, "Biomarkers: an indispensable addition to
the drug development toolkit," please register online at:

    About Thomson Reuters
    Thomson Reuters is the world's leading source of intelligent information
for businesses and professionals.  We combine industry expertise with
innovative technology to deliver critical information to leading decision
makers in the financial, legal, tax and accounting, scientific, healthcare and
media markets, powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs more than 50,000 people in 93 countries.  Thomson
Reuters shares are listed on the New York Stock Exchange (NYSE:   TRI); Toronto
Stock Exchange (TSX: TRI); London Stock Exchange (LSE: TRIL); and Nasdaq
(Nasdaq:   TRIN). For more information, go to


For further information:

For further information: Susan Besaw, Scientific, +1-215-823-1840, Web Site:

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890